V Bril

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy
    Vera Bril
    Department of Medicine, University of Toronto, Canada
    Diabetes Care 29:68-72. 2006
  2. ncbi request reprint Diagnostic tools for diabetic sensorimotor polyneuropathy
    Keri A Kles
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Curr Diabetes Rev 2:353-61. 2006
  3. doi request reprint The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study
    Samantha K Dunnigan
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada
    PLoS ONE 9:e89344. 2014
  4. pmc Evaluation of proxy tests for SFSN: evidence for mixed small and large fiber dysfunction
    Hamid Ebadi
    Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada
    PLoS ONE 7:e42208. 2012
  5. pmc Conduction slowing in diabetic sensorimotor polyneuropathy
    Samantha K Dunnigan
    Corresponding author Vera Bril
    Diabetes Care 36:3684-90. 2013
  6. doi request reprint IVIG and PLEX in the treatment of myasthenia gravis
    Vera Bril
    Department of Medicine Neurology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Ann N Y Acad Sci 1275:1-6. 2012
  7. doi request reprint Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis
    Carolina Barnett
    Department of Medicine, Division of Neurology, Toronto General Hospital, 5EC 309, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada
    J Neurol Neurosurg Psychiatry 84:94-7. 2013
  8. doi request reprint Treatments for diabetic neuropathy
    Vera Bril
    Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
    J Peripher Nerv Syst 17:22-7. 2012
  9. doi request reprint Electrophysiologic correlations with clinical outcomes in CIDP
    Vera Bril
    Division of Neurology, University Health Network, 5EC 309, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4 Canada
    Muscle Nerve 42:492-7. 2010
  10. ncbi request reprint Sural nerve sorbitol in patients with diabetic sensorimotor polyneuropathy
    Vera Bril
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Diabetes Care 27:1160-3. 2004

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy
    Vera Bril
    Department of Medicine, University of Toronto, Canada
    Diabetes Care 29:68-72. 2006
    ..We aimed to determine whether ranirestat, an aldose reductase inhibitor, maintains the improved nerve function observed in patients with diabetic sensorimotor polyneuropathy (DSP) after completing a 12-week nerve biopsy study...
  2. ncbi request reprint Diagnostic tools for diabetic sensorimotor polyneuropathy
    Keri A Kles
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Curr Diabetes Rev 2:353-61. 2006
    ..Early detection of neuropathy enables clinicians to prevent long-term complications like ulcers and amputations in patients with diabetes. The focus of this review is to describe the composite of tools necessary for diagnosis of DSP...
  3. doi request reprint The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study
    Samantha K Dunnigan
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada
    PLoS ONE 9:e89344. 2014
    ....
  4. pmc Evaluation of proxy tests for SFSN: evidence for mixed small and large fiber dysfunction
    Hamid Ebadi
    Division of Neurology, Department of Medicine, University Health Network, Toronto, Ontario, Canada
    PLoS ONE 7:e42208. 2012
    ....
  5. pmc Conduction slowing in diabetic sensorimotor polyneuropathy
    Samantha K Dunnigan
    Corresponding author Vera Bril
    Diabetes Care 36:3684-90. 2013
    ..We investigated the clinical and electrodiagnostic classifications of nerve injury in diabetic patients to detect evidence of conduction slowing in DSP...
  6. doi request reprint IVIG and PLEX in the treatment of myasthenia gravis
    Vera Bril
    Department of Medicine Neurology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Ann N Y Acad Sci 1275:1-6. 2012
    ..These studies support the choice of either IVIG or PLEX as comparable treatments in adult patients with moderate to severe MG...
  7. doi request reprint Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis
    Carolina Barnett
    Department of Medicine, Division of Neurology, Toronto General Hospital, 5EC 309, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada
    J Neurol Neurosurg Psychiatry 84:94-7. 2013
    ....
  8. doi request reprint Treatments for diabetic neuropathy
    Vera Bril
    Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
    J Peripher Nerv Syst 17:22-7. 2012
    ..The choice of treatment is guided by the clinical status of the individual patient...
  9. doi request reprint Electrophysiologic correlations with clinical outcomes in CIDP
    Vera Bril
    Division of Neurology, University Health Network, 5EC 309, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4 Canada
    Muscle Nerve 42:492-7. 2010
    ..44; P < 0.001) and Medical Research Council sum score (r = 0.38; P < 0.001). Overall, the change in electrophysiologic measures of NC in CIDP correlated with clinical response to treatment...
  10. ncbi request reprint Sural nerve sorbitol in patients with diabetic sensorimotor polyneuropathy
    Vera Bril
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Diabetes Care 27:1160-3. 2004
    ..In this study, we compared the results of sorbitol assays to determine the required sensitivity of analytical methods for nerve sorbitol measurements...
  11. ncbi request reprint Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy
    Vera Bril
    Department of Medicine, University of Toronto, Ontario, Canada
    Diabetes Care 27:2369-75. 2004
    ..An additional aim was to determine whether any changes in nerve function would manifest with AS-3201 therapy...
  12. ncbi request reprint Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy
    Vera Bril
    Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada
    Diabetes Care 25:2048-52. 2002
    ....
  13. ncbi request reprint Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies
    Vera Bril
    Toronto General Hospital, University of Toronto, University Health Network, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4
    Diabet Med 19:661-6. 2002
    ..Information comparing the VPT obtained with the Neurothesiometer with that with the Vibratron is available, but not for a similar comparison with the CASE IV (computer-assisted sensory examination device)...
  14. pmc Ranirestat for the management of diabetic sensorimotor polyneuropathy
    Vera Bril
    University Health Network, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 32:1256-60. 2009
    ..Aldose reductase inhibitors (ARIs) are potential disease modifiers for diabetes complications. We aimed to determine whether ranirestat, an ARI, could slow or reverse the course of diabetic sensorimotor polyneuropathy (DSP)...
  15. pmc Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy
    V Bril
    University Health Network, University of Toronto, Toronto, ON, Canada
    Diabet Med 26:240-6. 2009
    ..We aimed to assess the reproducibility of this modified tool, the mTCNS and to determine its validity relative to the precursor TCNS...
  16. doi request reprint Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV
    Vera Bril
    Department of Neurology, University Health Network, Toronto, Ontario, Canada
    Muscle Nerve 39:448-55. 2009
    ..035], and conduction block decreased significantly (treatment difference, -5.54%; 95% CI, -10.43, -0.64; P=0.027), particularly in the lower limbs. Overall, the data suggest that IGIV-C improves electrophysiologic parameters in CIDP...
  17. ncbi request reprint Sensory nerve area measurements in patients with diabetic neuropathy
    V Bril
    University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
    Electromyogr Clin Neurophysiol 41:59-63. 2001
    ..We conclude that current clinical trials do not include sufficient numbers of patients to show change in area measurements, particularly the area under the terminal segment of the curve...
  18. ncbi request reprint Limits of the sympathetic skin response in patients with diabetic polyneuropathy
    V Bril
    Toronto General Hospital, University of Toronto, Ontario, Canada
    Muscle Nerve 23:1427-30. 2000
    ..We conclude that current limitations inherent in SSR testing preclude its use as a reliable and consistent index of the autonomic dysfunction commonly encountered in diabetic patients...
  19. ncbi request reprint NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy
    V Bril
    The Toronto Hospital, Toronto, Ont, Canada
    Eur Neurol 41:8-13. 1999
    ..The use of the NIS-LL in clinical trials, together with other tests measuring nerve function, pain and risk of foot ulcer, provides the best opportunity to evaluate the efficacy of new therapeutic agents for the treatment of DPN...
  20. ncbi request reprint Long-term clinical outcome after transcervical thymectomy for myasthenia gravis
    V Bril
    Division of Neurology, The Toronto Hospital, Ontario, Canada
    Ann Thorac Surg 65:1520-2. 1998
    ....
  21. doi request reprint Variables associated with corneal confocal microscopy parameters in healthy volunteers: implications for diabetic neuropathy screening
    T Wu
    Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Canada
    Diabet Med 29:e297-303. 2012
    ....
  22. ncbi request reprint Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy
    B A Perkins
    Toronto General Hospital, University Health Network, University of Toronto, Canada
    Diabetes Care 24:748-52. 2001
    ..Based on the results of the present study, it might be hypothesized that improving glycemic control will lessen severity of DSP in terms of FD loss in subjects with diabetes...
  23. doi request reprint Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy
    P Hertz
    Division of Endocrinology and Metabolism Division of Neurology, University of Toronto, Toronto, ON, Canada
    Diabet Med 28:1253-60. 2011
    ....
  24. pmc Comparison of IVIg and PLEX in patients with myasthenia gravis
    D Barth
    Department of Pathology, University Health Network, Toronto General Hospital, Toronto, Canada
    Neurology 76:2017-23. 2011
    ....
  25. doi request reprint Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis
    B A Perkins
    Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    Diabet Med 27:1271-9. 2010
    ..We aimed to determine the variables associated with this paradoxical nerve function improvement...
  26. ncbi request reprint A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy
    L H Zinman
    Toronto General Hospital, University Health Network, Eaton Wing, 11 209, 200 Elizabeth Street, Toronto, ON, Canada
    Transfus Apher Sci 33:317-24. 2005
    ..IA appears to be a safe and efficacious therapy for patients with CIDP, but an appropriately powered clinical trial with stratification for disease duration is required...
  27. pmc Brachial plexopathy complicating Epstein-Barr virus infection in an adult
    D Dodig
    University Health Network, Division of Neurology, University of Toronto, Toronto General Hospital UHN, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
    Acta Myol 29:357-9. 2010
    ..We present a case of brachial plexopathy complicating prior EBV infection in a healthy adult...
  28. pmc Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation
    V Bril
    University Health Network, University of Toronto, Toronto, Canada
    Neurology 76:1758-65. 2011
    ..To develop a scientifically sound and clinically relevant evidence-based guideline for the treatment of painful diabetic neuropathy (PDN)...
  29. ncbi request reprint Status of current clinical trials in diabetic polyneuropathy
    V Bril
    Toronto General Hospital, UHN, University of Toronto, Ontario, Canada
    Can J Neurol Sci 28:191-8. 2001
    ..A discussion of clinical trials of agents directed towards relieving painful symptoms of diabetic polyneuropathy concludes this overview...
  30. ncbi request reprint Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Osaka, Japan
    J Pharmacol Sci 107:231-7. 2008
    ....
  31. ncbi request reprint Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Osaka, Japan
    J Pharmacol Sci 107:340-8. 2008
    ..Ranirestat should be a promising agent for the treatment of complications associated with diabetes, especially neuropathy...
  32. ncbi request reprint Multi-site testing with a point-of-care nerve conduction device can be used in an algorithm to diagnose diabetic sensorimotor polyneuropathy
    Bruce A Perkins
    Division of Endocrinology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 31:522-4. 2008
    ..We aimed to establish whether multi-nerve testing with a point-of-care nerve conduction device could be used to diagnose diabetic sensorimotor polyneuropathy...
  33. ncbi request reprint Carpal tunnel syndrome in patients with diabetic polyneuropathy
    Bruce A Perkins
    Beth Israel Deaconness Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes Care 25:565-9. 2002
    ..The prevalence of clinical CTS and the most efficient electrodiagnostic discriminators of CTS from diffuse neuropathy are uncertain...
  34. ncbi request reprint Comparison of sensory testing on different toe surfaces: implications for neuropathy screening
    Dimitri Dimitrakoudis
    University Health Network, Toronto General Hospital, University of Toronto, Ontario, Canada
    Neurology 59:611-3. 2002
    ..These results establish the importance of standardized screening methods for diabetic sensorimotor neuropathy in the clinic and in clinical research trials...
  35. ncbi request reprint Diabetic neuropathy: a review emphasizing diagnostic methods
    Bruce A Perkins
    EN 11 209, TGH, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4
    Clin Neurophysiol 114:1167-75. 2003
    ..Novel investigative techniques are highly promising, but their usefulness in the clinic setting remains limited at this time. This article presents an overview of diagnostic methods for DSP...
  36. ncbi request reprint Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments
    Lorne H Zinman
    University Health Network, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 27:1674-9. 2004
    ..The present study sought to determine the agreement between two common testing devices and to determine whether these are concordant in their association with predictor variables for diabetic sensory polyneuropathy...
  37. ncbi request reprint Early vascular risk factor modification in type 1 diabetes
    Bruce A Perkins
    N Engl J Med 352:408-9. 2005
  38. ncbi request reprint Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy
    Aaron I Vinik
    Strelitz Diabetes Institutes, Eastern Virginia Medical School, Norfolk, 23510, USA
    Muscle Nerve 32:619-25. 2005
    ..004; OR = 0.896). For patients with abnormal VDT, preserved sural SNAP identifies a patient population with less severe DPN who may respond to therapeutic intervention in clinical trials...
  39. ncbi request reprint Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy
    Bruce A Perkins
    Toronto General Hospital, 200 Elizabeth St, Room EN 12 217, Toronto, Ontario, Canada M5G 2C4
    Diabetes Care 29:2023-7. 2006
    ....
  40. ncbi request reprint Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy
    Bruce A Perkins
    EN 11 209, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
    Muscle Nerve 25:212-7. 2002
    ..Thus, unilateral evaluation of NCS in DSP is sufficient as a reference standard in clinical trials. We also conclude that great degrees of asymmetry in NCS results are reason to question inclusion of DSP patients in clinical trials...
  41. ncbi request reprint Surrogate therapeutic outcome measures in patients with myasthenia gravis
    Lorne Zinman
    Sunnybrook Health Sciences Centre, Toronto, Canada
    Muscle Nerve 37:172-6. 2008
    ....
  42. ncbi request reprint Muscle and nerve involvement in granulomatous mycosis fungoides
    Lili Naz Hazrati
    Department of Laboratory Medicine and Pathobiology, Banting Institute, 100 College Street, Toronto, Ontario M5G 1L5, Canada
    Muscle Nerve 36:860-5. 2007
    ..Based on a literature review and the course in our case, however, granulomatous mycosis fungoides seems to be an indicator of aggressive disease and ultimately a poor prognosis...
  43. ncbi request reprint Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis
    Lorne H Zinman
    Division of Neurology, 1382 13N, Toronto General Hospital, University Health Network, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada
    Muscle Nerve 33:694-6. 2006
    ..In addition, we confirmed the low sensitivity of RNS for ocular (18%) or generalized (47%) MG. The specificity of facial RNS for both muscles was 100% and, in certain circumstances, may obviate the need for further diagnostic testing...
  44. ncbi request reprint Neuromuscular function in survivors of the acute respiratory distress syndrome
    Michael J Angel
    Department of Medicine, Division of Neurology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Can J Neurol Sci 34:427-32. 2007
    ..Persistent neuromuscular complications of ARDS may contribute to the functional disability observed in these patients...
  45. ncbi request reprint Prognostic significance of thymomas in patients with myasthenia gravis
    Marc de Perrot
    Division of Thoracic Surgery, Toronto General Hospital, Ontario, Canada
    Ann Thorac Surg 74:1658-62. 2002
    ..The presence of thymoma may be a negative prognostic factor with respect to the outcome of myasthenia gravis (MG)...
  46. ncbi request reprint Diagnosis and management of diabetic neuropathy
    Bruce A Perkins
    Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Curr Diab Rep 2:495-500. 2002
    ..The management of DSP is centered on optimal glycemic control, diligent foot care, and pain control as a means of preventing the progression of DSP and reducing the morbidity associated with foot complications...
  47. ncbi request reprint Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial
    Lorne H Zinman
    Toronto General Hospital, Toronto, Ontario, Canada
    Diabetes Care 27:921-4. 2004
    ..The objective of this study was to determine whether LILT relieves the pain of DSP...
  48. ncbi request reprint Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial
    Aaron I Vinik
    Eastern Virginia Medical School, Norfolk, 23510, USA
    Clin Ther 27:1164-80. 2005
    ..The aim of this study was to assess the effects of ruboxistaurin (RBX) mesylate on nerve function and sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN)...
  49. ncbi request reprint IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial
    Lorne Zinman
    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Neurology 68:837-41. 2007
    ..We aimed to determine the effectiveness of IV immunoglobulin (IVIG) in the treatment of patients with myasthenia gravis (MG) and worsening weakness in a randomized, placebo-controlled, masked study...
  50. ncbi request reprint Diabetic neuropathies: a statement by the American Diabetes Association
    Andrew J M Boulton
    Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, U K
    Diabetes Care 28:956-62. 2005
  51. ncbi request reprint Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia
    Jaspreet Grewal
    Diabetes Care 29:473-4. 2006
  52. ncbi request reprint Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy
    Edward J Bastyr
    Lilly Research Laboratories, Indianapolis, Indiana, 46285, USA
    Clin Ther 27:1278-94. 2005
    ....
  53. doi request reprint Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
    Richard A C Hughes
    Department of Clinical Neuroscience, King s College London, Guy s Hospital, London, UK
    Lancet Neurol 7:136-44. 2008
    ..We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in patients with CIDP...